# 2025年12月26日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. Ghrelin通过促进肠干细胞再生缓解部分体照射诱导的胃肠急性放射综合征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444936)
**期刊：** Molecular medicine (Cambridge, Mass.)
**PMID：** 41444936
**DOI：** 10.1186/s10020-025-01399-9

### 第一部分 原文与翻译

**英文原标题：** Ghrelin mitigates partial body irradiation-induced gastrointestinal acute radiation syndrome by promoting intestinal stem cell regeneration.

> **英文摘要：**
> BACKGROUND: Gastrointestinal acute radiation syndrome (GI-ARS) is characterized by disruption of the intestinal barrier function, leading to bacterial translocation and sepsis. Intestinal stem cells are highly radiosensitive and dramatically reduced after radiation injury. Clusterin (Clu)-positive revival stem cells contribute to the restoration of intestinal stem cells. Ghrelin, a gastric peptide hormone, has been shown to improve intestinal integrity in models of inflammatory enteropathy. In this study, we investigated the effects of ghrelin on intestinal stem cell recovery and its potential to mitigate radiation-induced intestinal injury.
> 
> METHODS: Mice were subjected to 12 Gy partial body irradiation (PBI). Ghrelin at the doses of 2 to 6 nmol per mouse was administered daily for 4 consecutive days, starting at 24 h post-PBI, and survival was monitored for 30 days. To assess intestinal histology, cell proliferation, and intestinal stem cell markers, mice were treated with 6 nmol of ghrelin on days 1, 2, and 3 post-PBI, and on day 4 jejunal samples were collected for qPCR, immunofluorescence, and microcolony assays. Intestinal permeability was assessed in vivo by the leakage of gavage-fed 4-kDa FITC-dextran into the circulation.
> 
> RESULTS: Ghrelin administration significantly improved 30-day survival rate following 12-Gy PBI in a dose-dependent manner. Treatment with ghrelin restored villus length and enhanced intestinal barrier integrity. Ghrelin also significantly increased the expression of proliferation markers in the jejunum. Microcolony assays revealed that ghrelin reversed the decrease in BrdU-positive cells following PBI. The mRNA and protein expression of intestinal stem cell markers was decreased after PBI but was restored by ghrelin treatment. Finally, ghrelin significantly increased the population of Clu population following irradiation.
> 
> CONCLUSIONS: These findings indicate that ghrelin mitigates radiation-induced intestinal injury by promoting the expansion of Clu revival stem cells and the recovery of intestinal stem cells. This study highlights the therapeutic potential and identifies the mechanism of action of ghrelin as a medical countermeasure against GI-ARS.

> **中文摘要：**
> 背景：胃肠急性放射综合征（GI-ARS）的特征在于肠屏障功能受损，导致细菌移位和败血症。肠干细胞对辐射高度敏感，在放射损伤后显著减少。Clusterin（Clu）阳性的复苏干细胞有助于肠干细胞的恢复。作为一种胃肽类激素，ghrelin 已被证明可在炎症性肠病模型中改善肠道完整性。在本研究中，我们探讨了 ghrelin 对肠干细胞恢复的作用及其减轻放射诱导肠损伤的潜力。
> 
> 方法：小鼠接受 12 Gy 的部分体照射（PBI）。在 PBI 后 24 小时开始，每日给予 ghrelin 2 至 6 nmol/只，连续 4 天，并监测 30 天的生存情况。为评估肠组织学、细胞增殖及肠干细胞标志物，小鼠在 PBI 后第 1、2、3 天接受 6 nmol ghrelin 治疗，并于第 4 天收集空肠样本进行 qPCR、免疫荧光及微集落分析。体内通过灌胃 4-kDa FITC-葡聚糖并检测其循环系统渗漏来评估肠通透性。
> 
> 结果：ghrelin 给药以剂量依赖方式显著提高了 12 Gy PBI 后 30 天的生存率。ghrelin 处理恢复了绒毛长度并增强了肠屏障完整性。同时，ghrelin 显著提高了空肠中增殖标志物的表达。微集落实验显示，ghrelin 逆转了 PBI 后 BrdU 阳性细胞数量的下降。PBI 后肠干细胞标志物的 mRNA 和蛋白表达降低，而 ghrelin 处理可使其恢复。最后，ghrelin 在照射后显著增加了 Clu 阳性细胞的数量。
> 
> 结论：这些结果表明，ghrelin 通过促进 Clu 复苏干细胞的扩增及肠干细胞的恢复，从而减轻放射诱导的肠损伤。本研究揭示了 ghrelin 作为应对 GI-ARS 的医学对策的治疗潜力及其作用机制。

### 第二部分 AI 大师评价

本研究系统评估了 ghrelin 在部分体照射诱导胃肠急性放射综合征中的保护作用。研究采用小鼠模型，结合存活率、组织学、分子及功能多维指标，显示 ghrelin 可促进肠干细胞及 Clu 阳性复苏干细胞再生，恢复肠屏障功能。该发现为开发基于 ghrelin 的放射防护和肠道修复策略提供了新思路。其创新性在于揭示了 ghrelin 的干细胞层面作用机制，但仍需进一步临床验证其安全性与效果。

---

## 2. 甲磺酸纳法莫司塔作为血液净化的抗凝剂：系统综述与Meta分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444652)
**期刊：** Critical care (London, England)
**PMID：** 41444652
**DOI：** 10.1186/s13054-025-05813-w

### 第一部分 原文与翻译

**英文原标题：** Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis.

> **英文摘要：**
> OBJECTIVE: The nafamostat mesilate (NM) has shown good safety and effectiveness as anticoagulant for blood purification. This systematic review and meta-analysis aims to comprehensively compare NM with other anticoagulation strategies during blood purification.
> 
> METHOD: We searched the electronic databases of PubMed, Web of Science, Cochrane and Embase before 6 May 2025 on the application of NM in comparison with conventional anticoagulants, including unfractionated heparin, low-molecular-weight heparin, and regional citrate, or non-anticoagulant (NA) during blood purification. The protocol was registered in PROSPERO (CRD420251110062). We compared the incidence of bleeding, clotting and mortality with risk ratio (RR) and confidence intervals (95% CIs). Mean differences (MDs) with 95% CIs were employed for the comparisons of filter life and hospitalization length. Subgroup analysis was conducted according to the specific type of conventional anticoagulants and extracorporeal modalities of blood purification. Assessment of study quality, and sensitivity and publication bias analyses were conducted.
> 
> RESULT: In total, 16 studies consisting of 4349 participants were included in this systematic review and meta-analysis. Of them, 3956 patients received renal replacement therapy, and 393 underwent extracorporeal membrane oxygenation. NM showed a significantly lower risk of bleeding (RR: 0.53, 95% CI: 0.29-0.97, P = 0.040) and comparable filter life (MD: -1.23 h, 95% CI: -4.27-1.81, P = 0.428) compared with conventional anticoagulants. In comparison with NA, NM demonstrated a substantially longer filter life (MD: 4.84 h, 95% CI: 0.18-9.51, P = 0.042) and similar risk for bleeding complication (RR = 0.49, 95% CI: 0.18-1.35, P = 0.170). Of note, it was also associated with lower in-hospital mortality compared with NA (RR: 0.87, 95% CI: 0.77-0.97, P = 0.015).
> 
> CONCLUSION: NM is a safe and effective anticoagulant for blood purification, showing lower bleeding risk than conventional anticoagulants and longer filter life than NA, which is particularly suitable for patients at high risk of bleeding.

> **中文摘要：**
> 目的：甲磺酸纳法莫司塔（NM）已被证明在血液净化过程中具有良好的安全性和有效性。本系统综述与Meta分析旨在全面比较NM与其他抗凝策略在血液净化中的效果。
> 
> 方法：我们检索了截至2025年5月6日之前的PubMed、Web of Science、Cochrane和Embase数据库，筛选比较NM与常规抗凝剂（包括未分级肝素、低分子肝素和区域柠檬酸）或无抗凝（NA）应用于血液净化的研究。本研究方案已注册于PROSPERO（CRD420251110062）。我们采用风险比（RR）及95%置信区间（95% CI）比较出血、凝血和死亡率的发生情况；通过均数差（MD）及95% CI比较滤器寿命和住院时间。根据常规抗凝剂的具体类型及血液净化的体外方式进行了亚组分析，并评估研究质量、执行敏感性和发表偏倚分析。
> 
> 结果：共纳入16项研究，总计4349名受试者，其中3956名接受肾脏替代治疗，393名接受体外膜氧合治疗。与常规抗凝剂相比，NM显著降低出血风险（RR：0.53，95% CI：0.29–0.97，P＝0.040），滤器寿命相当（MD：−1.23小时，95% CI：−4.27–1.81，P＝0.428）。与NA相比，NM显著延长滤器寿命（MD：4.84小时，95% CI：0.18–9.51，P＝0.042），出血风险相似（RR＝0.49，95% CI：0.18–1.35，P＝0.170），且院内死亡率更低（RR：0.87，95% CI：0.77–0.97，P＝0.015）。
> 
> 结论：NM是一种安全且有效的血液净化抗凝剂，与常规抗凝剂相比可降低出血风险，与NA相比可延长滤器寿命，尤其适用于高出血风险患者。

### 第二部分 AI 大师评价

该研究系统综述并量化分析了甲磺酸纳法莫司塔在血液净化中的抗凝效果及安全性，通过整合16项研究结果，发现其出血风险低于传统抗凝剂，且相比无抗凝具有更长的滤器寿命和潜在的生存获益。研究方法规范，注册于PROSPERO并进行风险比与均数差分析，结果具有较高可信度。其创新性在于首次综合比较多种抗凝策略与NM的差异。然而，研究仍受限于纳入研究的异质性及数据来源的观察性特点。

---

## 3. 院外心脏骤停的状态转变轨迹：超越心肌活动的神经学结局研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444582)
**期刊：** Critical care (London, England)
**PMID：** 41444582
**DOI：** 10.1186/s13054-025-05815-8

### 第一部分 原文与翻译

**英文原标题：** State-transition trajectories in out-of-hospital cardiac arrest: neurological outcomes beyond myocardial activity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于院外心脏骤停患者，从动态状态转变轨迹的角度探讨患者在心肌活动恢复之后的神经学结局。这种研究视角突破了以往仅关注心脏复跳率的局限，强调长期神经系统功能恢复的重要性。通过分析状态转移及结局关联，文章可能为院外心脏骤停后的多阶段救治策略提供新思路。其创新性在于多维度建模患者恢复过程，但仍需临床数据的大样本验证以进一步巩固结论。

---

## 4. 通过神经导管重新连接迷走神经与心脏在小型猪右侧心脏迷走神经切断模型中可维持心脏功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41442503)
**期刊：** Science translational medicine
**PMID：** 41442503
**DOI：** 10.1126/scitranslmed.aea4306

### 第一部分 原文与翻译

**英文原标题：** Reconnecting the vagus nerve to the heart through nerve conduit preserves cardiac function in a minipig model of right cardiac vagotomy.

> **英文摘要：**
> The right vagus nerve is essential for cardiac homeostasis, and its intrathoracic resection can lead to postoperative cardiac complications. Strategies to restore vagal innervation after transection at the cardiac level remain lacking. Here, we show that early reconnection of the right vagus nerve using an implantable chitosan/poly-ε-caprolactone cuff-like nerve guidance conduit preserved cardiac mechanical function in adult male minipigs subjected to right cardiac vagotomy. Treated animals displayed improved global circumferential, longitudinal, and radial strains and reduced diastolic dyssynchrony. Histological analysis revealed partial repair with about 20% viable vagal fascicles, restoration of myocardial parasympathetic fibers, normalization of oxidative stress and aging markers, and prevention of interstitial fibrosis. These findings suggest that maintaining even limited vagal input prevents early cardiac remodeling by mitigating oxidative stress-induced premature senescence of cardiac cells. Reconnection of the right vagus nerve with chitosan/poly-ε-caprolactone cuff-like nerve guidance conduit may represent a therapeutic approach to preventing right vagotomy-induced heart failure after thoracic surgery or cardiothoracic transplantation.

> **中文摘要：**
> 右侧迷走神经对维持心脏稳态至关重要，其胸腔内切除可能导致术后心脏并发症。目前，尚缺乏在心脏水平切断后恢复迷走神经支配的有效策略。本研究显示，采用可植入的壳聚糖/聚-ε-己内酯袖套状神经导向管对右侧迷走神经进行早期重连，可维持接受右侧心脏迷走神经切断术的成年雄性小型猪的心脏机械功能。经治疗动物表现出整体环向、纵向及径向应变的改善，并且舒张期不同步性减轻。组织学分析显示约20%的迷走神经束实现部分修复，心肌副交感神经纤维得以恢复，氧化应激及衰老标志物恢复正常，并预防了间质性纤维化。研究结果提示，即便有限的迷走神经输入，也可通过减轻氧化应激诱导的心肌细胞早衰，从而防止早期心脏重构。利用壳聚糖/聚-ε-己内酯袖套状神经导向管重新连接右侧迷走神经，可能成为防治胸外科手术或心胸移植后右侧迷走神经切断所致心力衰竭的一种潜在治疗策略。

### 第二部分 AI 大师评价

该研究旨在探讨通过生物可降解神经导管实现右侧迷走神经重连以恢复心脏功能的潜在可行性。研究采用小型猪右侧心脏迷走神经切断模型，结果显示神经导管重建可显著改善心肌机械表现并减轻结构重构。组织学发现部分神经再生及心肌副交感支配恢复，提示迷走神经有限输入即可发挥保护作用。该工作创新性地将生物工程手段与心脏神经修复结合，但仍需进一步研究长远效果及在临床应用中的安全性与可行性。

---

## 5. 靶向 FcγR 的吞噬素簇在术前脓毒症相关继发感染中复活巨噬细胞功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41442500)
**期刊：** Science translational medicine
**PMID：** 41442500
**DOI：** 10.1126/scitranslmed.adv0313

### 第一部分 原文与翻译

**英文原标题：** FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.

> **英文摘要：**
> Sepsis-associated secondary infection often leads to a high mortality rate. Dysfunctional macrophages are primary contributors to inadequate antimicrobial defense in patients with sepsis-associated immunosuppression. Rejuvenating macrophage antibacterial capacity is beneficial for host defense against secondary infection. Here, we developed "BATMAN" (bacteria-targeted transformable macrophage nanorejuvenator), a self-assembling peptide nanoparticle to tackle sepsis-associated secondary infection by coordinating the arrest of invasive bacteria and rejuvenation of dysfunctional macrophages. BATMAN comprises a bacteria-targeting ubiquicidin peptide domain, bacterial lipase-sensitive cholesteryl hemisuccinate, an assembly-driving FFVLK domain, and the immunoglobulin G-derived tuftsin peptide. Upon activation by bacterial lipase, the particles undergo an inside-out transformation and assembly to expose and cluster the concealed tuftsin peptides for interaction with macrophage Fcγ receptors. Interaction of tuftsin clusters with macrophage Fcγ receptors enhanced bacterial phagocytosis and drove macrophage repolarization. In a cecal slurry-induced septic mouse model with secondary pulmonary infection, BATMAN treatment improved survival rates and rejuvenated the sepsis-compromised immune response to address polymicrobial- and multidrug-resistant pathogen-induced pulmonary infections. These findings suggest that BATMAN holds promise for further development as a therapeutic alternative for sepsis-associated secondary infection.

> **中文摘要：**
> 脓毒症相关的继发感染常常导致较高的死亡率。功能障碍的巨噬细胞是脓毒症相关免疫抑制患者抗菌防御不足的主要原因。恢复巨噬细胞的抗菌能力有助于宿主抵御继发感染。在此，我们开发了一种名为“BATMAN”（细菌靶向可变形巨噬细胞纳米复活剂）的自组装肽纳米颗粒，通过协调抑制侵袭性细菌与复活功能障碍巨噬细胞的作用，以应对脓毒症相关的继发感染。BATMAN 由细菌靶向的泛胱素肽结构域、细菌脂肪酶敏感的半琥珀酸胆固醇酯、驱动组装的 FFVLK 结构域以及源自免疫球蛋白 G 的吞噬素肽组成。在被细菌脂肪酶激活后，这些颗粒经历由内向外的形态转变和自组装，暴露并聚集原先被隐藏的吞噬素肽以与巨噬细胞 Fcγ 受体相互作用。吞噬素簇与巨噬细胞 Fcγ 受体的相互作用增强了细菌的吞噬作用并促进了巨噬细胞的再极化。在盲肠浆液诱导的继发性肺部感染脓毒症小鼠模型中，BATMAN 治疗改善了存活率，并恢复了被脓毒症损害的免疫反应，从而应对由多种细菌和多药耐药病原体引起的肺部感染。这些研究结果表明，BATMAN 作为一种治疗脓毒症相关继发感染的潜在替代疗法，具有进一步开发的前景。

### 第二部分 AI 大师评价

该研究旨在通过设计一种名为 BATMAN 的自组装肽纳米颗粒，复活脓毒症免疫抑制状态下功能受损的巨噬细胞。研究团队创新性地利用细菌脂肪酶触发纳米颗粒暴露吞噬素簇，与 Fcγ 受体结合以恢复吞噬功能并重塑巨噬细胞极化。动物实验证实 BATMAN 能显著提高继发感染时的存活率并改善抗菌免疫。该研究为针对脓毒症相关免疫障碍的精准免疫纳米疗法提供了新的思路，但仍需进一步验证其安全性与临床可行性。

---

速递结束，祝您工作愉快！